This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Impact Of Patent Expiration On Key Drugs Categories For 2012-2016 - A Survey Report

NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report

http://www.reportlinker.com/p01055031/Impact-of-Patent-Expiration-on-Key-Drugs-Categories-for-2012-2016----A-Survey-Report.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

TechNavio's analysts have conducted a survey on Impact of Patent Expiration on Key Drugs Categories for 2012-2016. The survey assessed the Impact of Patent Expiration on several key drugs categories such as Antipsychotic drugs, Antibiotics, ADHD drugs, Antacid drugs, Antiplatelet drugs, Asthma drugs, Diabetes drugs, Arthritis drugs, HIV drugs, Epilepsy drugs, and Cardiovascular drugs. The survey also covers the strategies adopted before patent expiration, strategies adopted to counter patent expirations, organizational impacts, and their sales impacts. Based on the overall factors, the impact of patent expiration on key drugs categories was studied for the period 2012-2016.

TechNavio's report, Impact of Patent Expiration on Key Drugs Categories for 2012-2016 - A Survey Report, has been prepared based on responses from over 200 participants across patented drug manufacturers, generic drug manufacturers, and a combination of both. The survey participants were selected from more than 15 top countries in the Global Pharmaceuticals market.

The vendors mentioned in the report are ABX GmbH, Ache Laboratorios SA, ACI Limited, Ajanta Pharma Ltd., Alphapharm Pty Ltd., AstraZeneca Europe, AstraZeneca India, Astrazeneca do Brasil LTDA, Baxter Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, CCL Pharmaceuticals Pvt. Ltd., Cipla Ltd., Covidien India Healthcare Limited, Dr Reddy's Laboratories Ltd., Eurofarma Laboratories Ltd., Ferring Pharmaceuticals, Genus Pharmaceuticals Ltd., Glenmark Pharmaceuticals, Healthcare Pharmaceuticals Ltd., Hospira Australia Pty Ltd., iNova Pharmaceuticals, LEO Pharma, Medley Pharmaceuticals Ltd., Merck Sharp & Dohme, MSD Pharmaceuticals Pvt. Ltd., Novartis International AG, Novartis de Colombia, Novartis farma Italy, Panacea Biotec Ltd., Pfizer Inc., PharmOut Pty Ltd., APP Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sandoz GmbH, Sandoz India Pvt Ltd., Sanofi SA, Schwabe Pharmaceuticals, Torrent Pharma, Vifor Pharma Ltd., Wanbury Ltd, and Wockhardt Ltd.

Key questions answered in this report:

What will the market size be in 2016 and what will the growth rate be?

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs